PSA and benign prostatic hyperplasia

被引:1
作者
Grall, J
Corbel, L
机构
[1] Cabinet Med, F-21000 Dijon, France
[2] Clin St Jeanne Arc, F-22015 St Brieuc, France
关键词
prostate-specific antigen; benign prostatic hyperplasia; prostate;
D O I
10.1016/S0003-4401(04)80006-8
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
In the opinion of many urologists, prostate-specific antigen (PSA), which is not specific of any disease, is not considered in the diagnosis and follow-up of benign prostatic hyperplasia (BPH). Nonetheless, prostate cancer diagnosis is based on PSA screening. PSA value is thus available for a majority of men above 50. Recent data suggest that there is a link between PSA value and BPH natural history, turning PSA into a tool. for BPH management and prevention of complications such as retention. It hasn't got into practice so far, as recommended criteria for PSA screening in BPH have not been issued. The debate over this topic is only at its beginning. (C) 2004 Elsevier SAS. Tous droits reserves.
引用
收藏
页码:S43 / S45
页数:3
相关论文
共 10 条
  • [1] *ANAES, 2003, PROGR FMC, V2, P24
  • [3] LONGITUDINAL EVALUATION OF PROSTATE-SPECIFIC ANTIGEN LEVELS IN MEN WITH AND WITHOUT PROSTATE DISEASE
    CARTER, HB
    PEARSON, JD
    METTER, J
    BRANT, LJ
    CHAN, DW
    ANDRES, R
    FOZARD, JL
    WALSH, PC
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (16): : 2215 - 2220
  • [4] Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma
    Mistry, K
    Cable, G
    [J]. JOURNAL OF THE AMERICAN BOARD OF FAMILY PRACTICE, 2003, 16 (02): : 95 - 101
  • [5] SERUM PROSTATE-SPECIFIC ANTIGEN IN A COMMUNITY-BASED POPULATION OF HEALTHY-MEN - ESTABLISHMENT OF AGE-SPECIFIC REFERENCE RANGES
    OESTERLING, JE
    JACOBSEN, SJ
    CHUTE, CG
    GUESS, HA
    GIRMAN, CJ
    PANSER, LA
    LIEBER, MM
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (07): : 860 - 864
  • [6] Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes
    Roehrborn, CG
    McConnell, JD
    Saltzman, B
    Bergner, D
    Gray, T
    Narayan, P
    Cook, TJ
    Johnson-Levonas, AO
    Quezada, WA
    Waldstreicher, J
    [J]. EUROPEAN UROLOGY, 2002, 42 (01) : 1 - 6
  • [7] Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen
    Steuber, T
    Nurmikko, P
    Haese, A
    Pettersson, K
    Graefen, M
    Hammerer, P
    Huland, H
    Lilja, H
    [J]. JOURNAL OF UROLOGY, 2002, 168 (05) : 1917 - 1922
  • [8] Relationship of body mass index and prostate specific antigen in a population-based study
    Thompson, IM
    Leach, R
    Troyer, D
    Pollock, B
    Naylor, S
    Higgins, B
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2004, 22 (02) : 127 - 131
  • [9] Villers A, 2003, PROG UROL, V13, P209
  • [10] Prostate specific antigen predicts the long-term risk of prostate enlargement: Results from the Baltimore Longitudinal Study of Aging
    Wright, EJ
    Fang, JY
    Metter, EJ
    Partin, AW
    Landis, P
    Chan, DW
    Carter, HB
    [J]. JOURNAL OF UROLOGY, 2002, 167 (06) : 2484 - 2487